These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30408225)

  • 21. A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Foley KG; Lavery A; Napier E; Campbell D; Eatock MM; Kennedy RD; Bradley KM; Turkington RC
    Sci Rep; 2021 Jun; 11(1):13061. PubMed ID: 34158588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study.
    McCain RS; McManus DT; McQuaid S; James JA; Salto-Tellez M; Reid NB; Craig S; Chisambo C; Bingham V; McCarron E; Parkes E; Turkington RC; Coleman HG
    Cancer Causes Control; 2020 Jan; 31(1):1-11. PubMed ID: 31786674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
    Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.
    Fareed KR; Soomro IN; Hameed K; Arora A; Lobo DN; Parsons SL; Madhusudan S
    World J Gastroenterol; 2012 Apr; 18(16):1915-20. PubMed ID: 22563171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
    Faron M; Cheugoua-Zanetsie AM; Thirion P; Nankivell M; Winter K; Cunningham D; Van der Gaast A; Law S; Langley R; de Vathaire F; Valmasoni M; Mauer M; Roth J; Gebski V; Burmeister BH; Paoletti X; van Sandick J; Fu J; Ducreux M; Blanchard P; Tierney J; Pignon JP; Michiels S;
    Eur J Cancer; 2021 Nov; 157():278-290. PubMed ID: 34555647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
    Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
    Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
    Messager M; Neofytou K; Chaudry MA; Allum WH
    Eur J Surg Oncol; 2015 Oct; 41(10):1316-23. PubMed ID: 26166786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
    Davies AR; Myoteri D; Zylstra J; Baker CR; Wulaningsih W; Van Hemelrijck M; Maisey N; Allum WH; Smyth E; Gossage JA; Lagergren J; Cunningham D; Green M;
    Br J Surg; 2018 Nov; 105(12):1639-1649. PubMed ID: 30047556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
    Turkington RC; Knight LA; Blayney JK; Secrier M; Douglas R; Parkes EE; Sutton EK; Stevenson L; McManus D; Halliday S; McCavigan AM; Logan GE; Walker SM; Steele CJ; Perner J; Bornschein J; MacRae S; Miremadi A; McCarron E; McQuaid S; Arthur K; James JA; Eatock MM; O'Neill R; Noble F; Underwood TJ; Harkin DP; Salto-Tellez M; Fitzgerald RC; Kennedy RD;
    Gut; 2019 Nov; 68(11):1918-1927. PubMed ID: 30852560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
    Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective cohort study of neoadjuvant therapy toxicity in the treatment of oesophageal adenocarcinoma.
    Bunting D; Berrisford R; Wheatley T; Humphreys L; Ariyarathenam A; Sanders G
    Int J Surg; 2018 Apr; 52():126-130. PubMed ID: 29455047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
    Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
    Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
    Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
    Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
    Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.
    Markar SR; Noordman BJ; Mackenzie H; Findlay JM; Boshier PR; Ni M; Steyerberg EW; van der Gaast A; Hulshof MCCM; Maynard N; van Berge Henegouwen MI; Wijnhoven BPL; Reynolds JV; Van Lanschot JJB; Hanna GB
    Ann Oncol; 2017 Mar; 28(3):519-527. PubMed ID: 28039180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy followed by surgery for advanced oesophageal cancer.
    Toxopeus EL; Talman S; van der Gaast A; Spaander VM; van Rij CM; Krak NC; Biermann K; Tilanus HW; Mathijssen RH; van Lanschot JJ; Wijnhoven BP
    Eur J Surg Oncol; 2015 Mar; 41(3):323-32. PubMed ID: 25534280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.